vs
Side-by-side financial comparison of Granite Ridge Resources, Inc. (GRNT) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
Granite Ridge Resources, Inc. is the larger business by last-quarter revenue ($128.3M vs $86.8M, roughly 1.5× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 4.3%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 18.9%).
Granite Ridge Resources, Inc. is an independent upstream energy company focused on the exploration, development, and production of oil, natural gas, and natural gas liquids. It operates low-cost, high-yield onshore hydrocarbon assets across key U.S. basins, primarily serving North American energy markets.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
GRNT vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $128.3M | $86.8M |
| Net Profit | $-47.0M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | — | -84.7% |
| Net Margin | -36.7% | — |
| Revenue YoY | 4.3% | 17.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.36 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $128.3M | — | ||
| Q4 25 | $105.5M | $86.8M | ||
| Q3 25 | $112.7M | $67.5M | ||
| Q2 25 | $109.2M | $60.0M | ||
| Q1 25 | $122.9M | $49.3M | ||
| Q4 24 | $106.3M | $73.7M | ||
| Q3 24 | $94.1M | $58.6M | ||
| Q2 24 | $90.7M | $31.1M |
| Q1 26 | $-47.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $14.5M | $-91.3M | ||
| Q2 25 | $25.1M | $-111.7M | ||
| Q1 25 | $9.8M | $-116.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $9.1M | $-83.5M | ||
| Q2 24 | $5.1M | $-97.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% |
| Q1 26 | — | — | ||
| Q4 25 | -34.5% | -84.7% | ||
| Q3 25 | 17.4% | -140.7% | ||
| Q2 25 | 19.0% | -189.8% | ||
| Q1 25 | 34.6% | -245.8% | ||
| Q4 24 | -6.5% | -117.5% | ||
| Q3 24 | 26.2% | -152.1% | ||
| Q2 24 | 24.1% | -327.6% |
| Q1 26 | -36.7% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 12.9% | -135.3% | ||
| Q2 25 | 23.0% | -186.2% | ||
| Q1 25 | 8.0% | -235.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 9.6% | -142.7% | ||
| Q2 24 | 5.6% | -312.2% |
| Q1 26 | $-0.36 | — | ||
| Q4 25 | $-0.19 | — | ||
| Q3 25 | $0.11 | — | ||
| Q2 25 | $0.19 | $-0.33 | ||
| Q1 25 | $0.07 | $-0.36 | ||
| Q4 24 | $-0.09 | $-0.24 | ||
| Q3 24 | $0.07 | $-0.28 | ||
| Q2 24 | $0.04 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $297.0M |
| Total DebtLower is stronger | $26.3M | — |
| Stockholders' EquityBook value | $545.6M | $698.6M |
| Total Assets | $1.2B | $913.2M |
| Debt / EquityLower = less leverage | 0.05× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | — | $301.2M | ||
| Q1 25 | — | $359.7M | ||
| Q4 24 | — | $323.8M | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | — | $412.5M |
| Q1 26 | $26.3M | — | ||
| Q4 25 | $367.8M | — | ||
| Q3 25 | $300.0M | — | ||
| Q2 25 | $275.0M | — | ||
| Q1 25 | $250.0M | — | ||
| Q4 24 | $205.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $545.6M | — | ||
| Q4 25 | $605.8M | $698.6M | ||
| Q3 25 | $643.9M | $702.3M | ||
| Q2 25 | $642.5M | $698.5M | ||
| Q1 25 | $631.4M | $767.9M | ||
| Q4 24 | $635.4M | $710.4M | ||
| Q3 24 | $660.6M | $773.5M | ||
| Q2 24 | $665.3M | $768.5M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $913.2M | ||
| Q3 25 | $1.1B | $904.9M | ||
| Q2 25 | $1.1B | $907.4M | ||
| Q1 25 | $1.1B | $966.7M | ||
| Q4 24 | $1.0B | $910.4M | ||
| Q3 24 | $1.0B | $991.1M | ||
| Q2 24 | $990.5M | $964.3M |
| Q1 26 | 0.05× | — | ||
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.47× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.40× | — | ||
| Q4 24 | 0.32× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $58.3M | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | 47.1% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $58.3M | — | ||
| Q4 25 | $64.5M | $-52.6M | ||
| Q3 25 | $77.8M | $-78.7M | ||
| Q2 25 | $78.0M | $-67.4M | ||
| Q1 25 | $76.1M | $-103.7M | ||
| Q4 24 | $68.2M | $-73.3M | ||
| Q3 24 | $74.7M | $-59.0M | ||
| Q2 24 | $64.2M | $-98.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | — | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | — | $-98.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | — | -317.9% |
| Q1 26 | 47.1% | — | ||
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 5.36× | — | ||
| Q2 25 | 3.11× | — | ||
| Q1 25 | 7.75× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.25× | — | ||
| Q2 24 | 12.58× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GRNT
| Oil sales | $103.4M | 81% |
| Natural gas and related product sales | $24.8M | 19% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
